22 Background: We compared drugs (imipenem; doripenem) doses (500 mg; 1g) and
Introduction

43
Pseudomonas aeruginosa continues to be a major problem in the nosocomial 44 setting. Increasing rates of resistance makes the development of effective therapeutic 45 regimens problematic.
46
Doripenem is a new carbapenem antibiotic with potent activity against 47 Pseudomonas aeruginosa. Pre-clinical studies have indicated that it is highly stable to 48 the ampC enzyme seen in this pathogen and that it interacts differently with the 49 pathogen regarding oprD down-regulation, resulting in lower MIC shifts, in at least 50% 50 of instances (6) . Clinically, the use of the prolonged infusion has been shown to have a In order to ascertain the contribution of each we decided to study three different 61 isogenic isolates: a wild-type isolate (PA01); an isolate with a stably derepressed 62 chromosomal ampC enzyme (ampC β-lactamase production is markedly increased 63 when a mutation in the repressor system occurs and the increase is stable and not 64 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from dependent upon the presence or absence of drug); an isolate with a defined down-regulation of oprD (oprD is a carbapenem-specific transport porin; when down-66 regulated, less drug is available per unit time in the periplasmic space). In addition, we 67 decided to examine both doripenem and imipenem to ascertain the impact of differing 68 potency and interaction with oprD downregulation. Finally, we hypothesized that 69 infusion time would have an impact. Therefore we studied doripenem at a 500 mg dose 70 with a one hour infusion, a 500 mg dose with a 4 hour infusion and a 1 g dose with a 71 four hour infusion. Imipenem's stability is such that a 4 hour infusion cannot be 72 recommended clinically. We therefore decided to examine 500 mg every 6 hours with a Where Effect is the bacterial burden at 24 hours in treated animals (Log 10 (CFU/g));
184
Econ is the bacterial burden at 24 hours in the no-treatment control animals (Log 10
185
(CFU/g)); E max (Log 10 (CFU/g)) is largest bacterial kill obtainable with the time frame calculated for each regimen and for each organism and is displayed in Table 1 .
222
Because of the previous observations of Tam et al (9), the Time > 6.2 x MIC was also 223 calculated and these are displayed in Table 1 .
224
These times were used to create an inhibitory sigmoid-Emax effect model. The and was equivalent to imipenem in the stably de-repressed mutant. In the oprD mutant, 254 however, the MIC was 2 mg/L for doripenem and 16 mg/L for imipenem, validating the 255 previous observations of Mushtaq (6) .
256
We examined both cell kill activity of the regimens and we looked at emergence of 500 mg producing a kill of 4.07 Log 10 (CFU/ml).
266
For the stably-derepressed isogenic mutant of PA01, the hierarchy of effect was 
273
(CFU/ml), respectively. As in the other experiments, the best cell kill was seen with the 274 doripenem 1g, 4 hour infusion regimen, at 4.24 Log 10 (CFU/ml).
275
When one examines all the regimens, it becomes apparent that the differences in 
311
It is important to note that of all the regimens for all the isogenic isolates, only the 
